Futura Medical's (LON:FUM) James Barder speaks to Proactive London's Andrew Scott following the news they've completed initial laboratory and optimisation work on its Dermasys® cannabidiol gel (CBD100). He says the studies have demonstrated highly efficient penetration of cannabidiol into and through the skin and that the results have shown its superiority to an established, marketed, comparator product. Barder adds they've now started to explore commercialisation options for CBD100.
Futura Medical assessing commercialisation options for CBD100
Quick facts: Futura Medical PLC
Price: 14.5 GBX
Market Cap: £35.62 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE